CoChat

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform

Open access
Li, Danni, Mielke, Michelle M. · 2019 · Neurology and Therapy

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ 42 ), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10 −16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ 42 , P-tau, T-tau, and NfL levels and discuss future directions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40120-019-00164-5

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 147

Metadata

Authors
Li, D., & Mielke, M. M.
Affiliations
  • University of Minnesota (US)
  • Mayo Clinic (US)
Corresponding author
Mielke, Michelle M.
Venue
Neurology and Therapy
Published
2019-12
Volume
8
Issue
S2
Pages
73-82
ISSN
  • 2193-6536 (ISSN-L)
  • 2193-8253
OpenAlex
W2994668634
Cited by
147
References
54
Citations by year
2026: 12 · 2025: 20 · 2024: 24 · 2023: 29 · 2022: 25 · 2021: 29 · 2020: 6 · 2019: 1
FWCI
1.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Neurology and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Institute on Aging (U01AG006786, R01AG049704, R01AG059654)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
Keywords
Alzheimer's disease, blood-based biomarkers, single molecule array, amyloid-beta 42, phosphorylated tau, total tau, neurofilament light chain, early detection of dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform. https://app.cochat.ai/papers/10.1007/s40120-019-00164-5
The paper
Li, D., & Mielke, M. M. (2019). An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform. Neurology and Therapy. https://doi.org/10.1007/s40120-019-00164-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.